At a glance
ClinicalIndex Comparison RecordN/ACompleted· 67 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non-Interventional, Observational Phase IV Study to Evaluate Safety of Rituximab (Mabthera®) in Combination With Chemotherapy in Patients Treated With CD20+ Β Chronic Lymphocytic Leukemia
In Brief
An observational study evaluating Rituximab for Lymphocytic Leukemia, Chronic. Completed, enrolled 67 participants across 9 sites.
Detailed Summary
This observational study will evaluate the safety and efficacy of rituximab in combination with chemotherapy in first- and second-line treatment of participants with cluster of differentiation 20 (CD20)-positive B-cell chronic lymphocytic leukemia. Data will be collected from eligible participants receiving rituximab according to the Summary of Product Characteristics (SPC) during 6 months of treatment.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsLymphocytic Leukemia, Chronic
CountriesGreece
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2012
First PostedMay 2012
Primary CompletionNov 2015
TodayJul 2026
First PostedMay 31, 2012
Enrollment StartApr 1, 2012
Primary CompletionNov 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 14.1 years ago
Interventions
Rituximabdrug
Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.